


Attorney Docket No.: 0017.200-US



SH

*OSU*  
*Box Sequence*  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schnorr et al.

Confirmation No: 5362

Serial No.: 09/784,554

Group Art Unit: 1651

Filed: February 16, 2001

Examiner: To be assigned

For: Family 44 Xyloglucanases

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box Sequence  
U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Notice to Comply with Sequence Rules
2. Copy of Notice to Comply with Sequence Rules
3. Disk Containing Sequence Listing

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box Sequence  
U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

on April 8, 2002.

Julie Tabarovsky  
(name of person mailing paper)

*J. Tabarovsky*  
(signature of person mailing paper)



Attorney Docket No.: 10084.200-US

PATENT

#10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schnorr et al.

Confirmation No: 5362

Serial No.: 09/784,554

Group Art Unit: 1651

Filed: February 16, 2001

Examiner: To be assigned

For: Family 44 Xyloglucanases

**RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE REQUIREMENTS**

Box Sequence  
U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Sir:

This paper is in response to the Notice to Comply with Sequence Requirements dated February 13, 2002. The Notice stated that the computer readable form that was filed on October 24, 2001 was unreadable.

Applicants therefore enclose another computer readable form of the Sequence Listing. The content of the paper copy that was filed with the application and of the enclosed computer readable form is the same. This submission contains no new matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

Date: April 8, 2002



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/784,554	02/16/2001	Kirk Schnorr	10017.200-US

25908

NOVOZYMES NORTH AMERICA, INC.  
C/O NOVO NORDISK OF NORTH AMERICA, INC.  
405 LEXINGTON AVENUE, SUITE 6400  
NEW YORK, NY 10174



CONFIRMATION NO. 5362

## FORMALITIES LETTER



\*OC000000007466737\*

Date Mailed: 02/13/2002

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE